Cited by 286Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design

Open access
Trivedi, Madhukar H., McGrath, Patrick J., Fava, Maurizio, Parsey, Ramin V., Kurian, Benji T., Phillips, Mary L., Oquendo, Maria A., Bruder, Gerard +14 more·2016·Journal of Psychiatric Research

Abstract

Unlabelled Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 300 participants with early onset (≤30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.Clinical trial registration Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC). Identifier: NCT01407094. URL: http://clinicaltrials.gov/show/NCT01407094.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2016.03.001

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The nature of care as usual or treatment as usual depends heavily on the health care system of the country and the study setting, ranging from almost no care to specialised mental health care by well-trained professionals.

    “The nature of care as usual or treatment as usual depends heavily on the health care system of the country and the study setting, ranging from (almost) no care to specialised mental health care by well-trained professionals. 594”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Wallace ML Frank E Kraemer HC A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials JAMA Psychiatry 2013 70 1241 1247 24048258 PMC10289205

Cited by

Sorted by citations

Authors
Trivedi, M. H., McGrath, P. J., Fava, M., Parsey, R. V., Kurian, B. T., Phillips, M. L., Oquendo, M. A., Bruder, G., Pizzagalli, D., Toups, M., Cooper, C., Adams, P., Weyandt, S., Morris, D. W., Grannemann, B. D., Ogden, R. T., Buckner, R., McInnis, M., Kraemer, H. C., Petkova, E., Carmody, T. J., & Weissman, M. M.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • New York State Psychiatric Institute (US)
  • Stony Brook University (US)
  • University of Pittsburgh (US)
  • Harvard University (US)
  • Columbia University (US)
  • University of Michigan (US)
  • Stanford University (US)
  • New York University (US)
Corresponding author
Trivedi, Madhukar H.
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2016-07
Volume
78
Pages
11-23
ISSN
0022-3956 (ISSN-L)
OpenAlex
W2298299786
Cited by
286
References
102
Citations by year
2026: 16 · 2025: 32 · 2024: 31 · 2023: 26 · 2022: 28 · 2021: 23 · 2020: 36 · 2019: 34 · 2018: 26 · 2017: 21 · 2016: 7 · 2015: 2 · 2014: 2 · 2013: 2
FWCI
23.77
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychiatric Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Columbia Academic Commons (Columbia University)
Funders
National Institute of Mental Health of the National Institutes of Health (U01MH092221, U01MH092250)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
major depressive disorder, antidepressant response, treatment moderators, biosignatures, sertraline, bupropion, biomarkers, resting-state functional connectivity, diffusion tensor imaging, arterial spin labeling, EEG, treatment-resistant depression
MeSH terms
Adult, Antidepressive Agents, Brain, Major Depressive Disorder, Double-Blind Method, Electroencephalography, Female, Humans, Magnetic Resonance Imaging, Male, Psychiatric Status Rating Scales, Quinazolines, Research Design, Biomarkers, Treatment Outcome, Patient Selection, Sertraline, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review